My name is Joe Daly. I am working at Intel to develop solutions to compute and data movement issues realted to the volumes of data related to short read sequencing.
-
Joe Daly
Intel Corp. - Integrated Analytics -
Brian Bramlett at Intel has been working on for visualizing Illumina data for quality control. I've seen some wonderful screen shots of his work, but don't have permission to share them. I think they would be of interest to many on this site. Perhaps you are connected to him or that work? -
Hi Joe, Your introduction sounds interesting - would you be able to tell us a little more about your work? What compute projects are you working on?The more you know, the more you know you don't know. —AristotleComment
-
Hi Mike,Originally posted by cariaso View Post
We are still trying to figure out how to release Brian's work. Let's get a phone call for the three of us to talk.
JoeJoe Daly
Intel Corp. - Integrated AnalyticsComment
-
Hi Anthony,
We are trying to address a few issues for labs who are new to short read sequencing, or labs who don't have budgets for large support staff. The first objective is a turn key startup which integrates a baseline level of storage, compute, cluster technology, and an application toolbox so startup is seemless. Secondly, we are selectively applying Intel QuickAssist front side bus accelerators to improve the compute/[$$, cubic foot, watt] performance. As you stated in your blog, we are moving cautiously because many of the applications are still very fluid. It is also just difficult to stay ahead of Moore's law for over a long period of time, so the selection process needs to focus on those handful of things that have unlimited compute demand. We also hope to make the process of finding and installing bioinformatics apps very painless. By getting a platform that is based on open technology, and getting enough volume, we expect to stabilize execution targets for developers. I'm in Portland, OR so it woud be easy to have a phone follow up.
Thanks, JoeJoe Daly
Intel Corp. - Integrated AnalyticsComment
-
Hi Joe,
Thanks for the excellent summary - I appreciate you sharing that information with us.
I also very much appreciate what you're saying about helping new groups to get set up with the technology. Although the GSC is beyond that phase now, there are clearly some major hurdles to getting everything in place. I'm somewhat curious about the scalability of what you're working on, in terms of whether you expect it will be useful for large groups as well. (Although I understand getting an established group to switch would be much more difficult than getting in at the ground level.)
I hope I'm not asking too many questions. - and thanks again for taking the time to reply! (=The more you know, the more you know you don't know. —AristotleComment
-
Joe,
I would be curious too about the scalability of your start-up solution. We have had 1 solexa for a year, being upgraded to GA2, along with a new GA2. So we have cleared some of the startup hurdles, only to catch the newer ones and work on overcoming them
--
bioinfosmComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment